Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark submits clinical trial application for GBR 1302 novel antibody
GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s BEAT platform. The drug candidate has the potential to be used in the treatment of an array of
GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s BEAT platform. The drug candidate has the potential to be used in the treatment of an array of
The drug candidate, dubbed TS23, is in phase I trials, evaluating safety and biomarker efficacy. Phase II trials, which will identify safety and efficacy in acute thrombotic vascular,
The company carried out the randomized, double-blind, placebo-controlled trial of XP23829 in 33 sites in the US in 200 subjects with moderate-to-severe chronic plaque-type psoriasis. They were randomized
The regimen uses a combination of two components based on Crucell Holland’s AdVac technology and MVA-BN technology from Bavarian Nordic. The deal includes a 5-year commitment, with options
Last month, InSite Vision signed a definite agreement with Canadian drug maker QLT for $0.25 and 0.30 per share. The deal however included a built in clause that
The company is seeking approval depending on the Reprieve clinical study results, which determined the long-term maintenance of efficacy and safety of Fanapt antipsychotic agent. The agency is
The companies started the collaboration in 2014 and made better progress in the discovery of new compounds with activity against gram-positive and gram-negative bacteria. Under the partnership, which
The drug was being tested in children with nonalcoholic steatohepatitis (NASH), which is a liver inflammation caused by a buildup of fat in the liver. The study involved
Both the companies signed license deal in December 2014. The termination starts on 7 January 2016. Anthera will regain all worldwide rights for blisibimod without cost and Zenyaku
The new antibiotics aim to kill a germ called Staphylococcus aureus, or staph, and antibiotic resistant strains known as methicillin-resistant Staphylococcus aureus (MRSA). Unlike the contemporary antibiotics, the